Trial Profile

Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Urogenital cancer
Focus Biomarker; Pharmacodynamics
Acronyms RESPONDER

Most Recent Events

06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Oct 2021 Results (n=56) assessing to identify early changes in T-cell subsets that underlie anti-PD1 efficacy in metastatic urothelial cancer patients, published in the Clinical Cancer Research.
19 Aug 2021 Planned End Date changed from 21 Aug 2020 to 19 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com